Roche revised package insert for the antimalaria drug includes a bold-faced warning of fatalities that have occurred due to severe reactions, including Stevens-Johnson Syndrome and toxic epidermal necrolysis. Insert also restricts use of the drug in patients with suspected chloroquine-resistant Pjasmodium falciparum malaria and notes that Fansidar may be used prophylactically for people traveling to areas where chloroquine-resistant P. falciparum malaria is endemic. Roche sent the revised insert to 200,000 doctors and pharmacists the week of Aug. 19.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.